In a new study from The University of Texas M. D. Anderson Cancer Center, researchers found that cystoscopy, the standard for screening for recurrence of early-stage bladder cancer, is a cost-effective method of detecting tumors.
Adding other tests to cystoscopy increases the cost, as well as the number of false positives that may result in emotional distress and unnecessary procedures, the investigators include.
The study was presented today in advance of the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium. Jose Karam, M.D., a fellow in M. D. Anderson's Department Genitourinary Oncology, presented the findings.
"Our research potentially will enable clinicians to make judicious use of the available ancillary 'urinary markers,' which would translate into costs savings plus less anxiety for bladder cancer patients," said Ashish Kamat, M.D., associate professor of Urology and director of M. D. Anderson's Urologic Oncology Fellowship Program.
"The tests frequently added to cystoscopy have many more false positives than commonly believed, and they can lead to unnecessary work-ups. Our findings also may help reduce the cost of caring for bladder cancer patients, which currently in is the range of $4 billion annually," continued Kamat, the study's senior author.
Early-stage bladder cancer, or non-muscle invasive bladder cancer (NMIBC), has a high rate of recurrence. Patients are tested every three to six months, often for the rest of their lives, with the goal of catching the cancer early if it returns.
Cystoscopy is an outpatient procedure in which a tiny tube with a small camera attached is inserted through the urethra into the bladder. Doctors then are able to visually examine the inside of the bladder for tumors. Many times, in efforts to ensure accuracy and early detection of bladder cancer recurrence, other tests are added to cystoscopy.
"In this study, we wanted to identify which bladder surveillance method provides acceptable tumor detection rate while minimizing costs," said Karam.
Kamat and his colleagues prospectively evaluated 200 M. D. Anderson patients with NMIBC. They compared the accuracy and cost of cystoscopy alone and cystoscopy combined with:
- Cytology, examining bladder cells with a microscope
- NMP22, a urine test that tests the level of NMP22 protein
- FISH (fluorescence in situ hybridization), a urine test for chromosomal aberrations in bladder cells
- NMP22 confirmed by FISH
But despite their added costs, additional tests did not give better results. Cystoscopy was most cost effective in finding tumors. Cystoscopy had two false positives, the fewest of any test, while cystoscopy plus FISH had the most false positives at 30.
"There are some who believe that the ancillary tests have the property to predict recurrences early," Kamat said. "In order to account for this, we took into account tumors detected later - at the first follow-up - to assess whether the tests added to detection rates. Our results suggest that, while the ancillary tests did turn positive prior to actual tumor recurrence in a handful of patients, the vast majority were still falsely positive."
Kamat said he would like to see the findings of this study confirmed in the near future by a multi-center co-operative study.
Explore further: Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC